Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ceramide kinase-like protein (CERKL) is a gene primarily expressed in the retina whose mutations are linked to autosomal recessive retinal degenerations such as retinitis pigmentosa and cone-rod dystrophy[2][1]. Despite structural similarity to ceramide kinase, CERKL does not phosphorylate ceramide or other tested lipid substrates[2][3]. Instead, CERKL exerts crucial protective functions in retinal cells by binding mRNA and participating in mRNA metabolism, interacting with protein complexes related to translation, and associating with stress granules, P-bodies, and microtubules[1]. It also helps regulate autophagy by stabilizing SIRT1 and maintains mitochondrial/oxidative stress resistance through interaction with mitochondrial thioredoxin 2[2][4]. Disease-associated mutations in CERKL impair these protective roles, leading to progressive retinal degeneration and photoreceptor cell death[2][1][4]. No approved therapeutic drugs directly target CERKL, and its role is not as a classical enzyme or receptor, but rather as a multifunctional regulator critical for retinal health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ceramide kinase-like protein (CERKL).